Click the button below to contact us or submit your feedback about this product.
ImmunoArrayᵀᴹ Tumor-Associated Autoantibody (TAAb) Detection Service/Antigen Microarray (CAT#: NA-0726-FY4)
Tumor-Associated Autoantibody Detection Service is a premier, ultra-sensitive antigen microarray platform engineered for non-invasive liquid biopsy research and high-throughput immune profiling. By immobilizing 60 meticulously curated tumor-associated antigens onto an advanced 3D microchip matrix, the platform captures target proteins in their native, biologically active conformations. Capable of processing 16 samples per slide with a mere 5 μL sample volume, it enables parallel dual-isotype (IgG/IgM/IgA) detection, bypassing the limitations of traditional single-plex ELISAs at a fraction of the cost. Equipped with built-in Ig/anti-Ig normalization pairs and an expansive 1-65000 dynamic range, it serves as an indispensable discovery engine for establishing multi-marker autoantibody signatures, detecting early-stage malignancies, and tracking complex autoimmune diseases.
| Specifications | |
|---|---|
| Size | Standard microchip substrate layout (Standard glass slide format) |
| Throughput Level | High-throughput multi-slide parallel processing; 16 samples can be processed simultaneously per individual slide |
| Protein Count | Features 60 tumor-associated autoantigens (derived from comprehensive peer-reviewed literature reviews) |
| Proteome Coverage | Target-specific disease coverage (Designed to screen for over 120 autoantibodies per well instead of broad genome coverage) |
| Full-Length Protein Ratio | High conformational fidelity (Optimized to maintain proteins in their native, three-dimensional structure) |
| Expression System | High-quality eukaryotic and purified production lines (Engineered to secure natural antigen conformations) |
| Purification Method | Advanced affinity and high-purity antigen isolation |
| Arraying Technology | Precise array deposition onto a proprietary three-dimensional (3D) microchip surface |
| Quality Control | Integrated internal Ig and anti-Ig control pairs in each array for rigorous normalization and quantitative validation |
| Features | High Multiplexing & Micro-Volume Efficiency: Capable of screening over 120 multiplexed autoantibodies simultaneously within a single reaction well, requiring a minimal specimen volume of only 5 μL of serum or alternative biofluids. Dual-Isotype Fluorescence Detection: Utilizes sophisticated fluorophore-conjugated secondary antibodies to achieve parallel detection of two distinct antibody classes (e.g., IgG/IgM or IgA) on a single array, drastically conserving precious clinical samples. Superior Analytical Sensitivity & Range: Provides exceptional signal performance with a wide dynamic range spanning from 1 to 65000 Relative Fluorescence Units (RFU), enabling robust semi-quantitative profiling via standard calibration curves. Unmatched Cost Efficiency: Delivers dense multi-cancer autoantibody fingerprinting at an economical price point, reducing experimental overhead to less than 1/10 the cost of traditional single-plex ELISA kits. |
| Application Fields | Early Cancer Diagnostics & Liquid Biopsies: Serving as a non-invasive early warning system for oncology screening (e.g., lung, breast, prostate, and colorectal cancers) by capturing robust antibody signals before macroscopic clinical symptoms emerge. Oncology Biomarker & Immunotoxicity Profiling: Building multi-parameter "autoantibody signatures" to gauge tumor presence, molecular disease states, cancer recurrence risks, and monitoring immune-related adverse events (irAEs) during immunotherapy. Autoimmune & Allergic Disease Mapping: Profiling dense autoantibody footprints for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), diabetes, Sjøgren's syndrome, scleroderma, and hypersensitivity disorders. Infectious Diseases & Vaccine Development: Assessing baseline humoral responses and tracking post-vaccination autoimmune tracking for viral pathogens like SARS-CoV-2, influenza, and Respiratory Syncytial Virus. Transplantation & Drug Development: Evaluating organ transplantation efficacy, executing high-throughput drug target screenings, and verifying patient stratification across clinical trial cohorts. |
DatasheetFor Research Use Only | Not For Clinical Use
Related products
- ImmunoArrayᵀᴹ Common Autoimmune Disease-Related Autoantibody Detection Service (Antigen Microarray) (CAT#: NA-0726-FY9)
- ImmunoArrayᵀᴹ Neuroimmune-Related Autoantibody Detection Service (CAT#: NA-0726-FY15)
- ImmunoArrayᵀᴹ Autoimmune Myocarditis and Myositis-Related Autoantibody Detection Service (Antigen Microarray) (CAT#: NA-0726-FY10)
- ImmunoArrayᵀᴹ Human Milk Oligosaccharides (HMO) Glycan Microarray (CAT#: NA-0726-FY33)
- ImmunoArrayᵀᴹ Recombinant Pan-fucose-binding Lectin (C-His tag) (CAT#: NA-0726-FY43)
- ImmunoArrayᵀᴹ Lectin Microarray (CAT#: NA-0726-FY2)
- ImmunoArrayᵀᴹ MUC1 Glycopeptide Microarray (CAT#: NA-0726-FY38)
- ImmunoArrayᵀᴹ Antiphospholipid Syndrome (APS) and Neutrophil Extracellular Traps (NETs) Related Citrullinated Protein Autoantibody Detection Service (CAT#: NA-0726-FY18)
Services:
Resource:
Applications:
Online Inquiry